222 related articles for article (PubMed ID: 34187851)
1. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Ferrarotto R; Amit M; Nagarajan P; Rubin ML; Yuan Y; Bell D; El-Naggar AK; Johnson JM; Morrison WH; Rosenthal DI; Glisson BS; Johnson FM; Lu C; Mott FE; Esmaeli B; Diaz EM; Gidley PW; Goepfert RP; Lewis CM; Weber RS; Wargo JA; Basu S; Duan F; Yadav SS; Sharma P; Allison JP; Myers JN; Gross ND
Clin Cancer Res; 2021 Aug; 27(16):4557-4565. PubMed ID: 34187851
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Hanna GJ; O'Neill A; Shin KY; Wong K; Jo VY; Quinn CT; Cutler JM; Flynn M; Lizotte PH; Annino DJ; Goguen LA; Kass JI; Rettig EM; Sethi RKV; Lorch JH; Schoenfeld JD; Margalit DN; Tishler RB; Everett PC; Desai AM; Cavanaugh ME; Paweletz CP; Egloff AM; Uppaluri R; Haddad RI
Clin Cancer Res; 2022 Feb; 28(3):468-478. PubMed ID: 34667025
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Yoo SY; Mathias M; Han H; Seebach F; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2023 Nov; 24(11):1196-1205. PubMed ID: 37875144
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
Wu D; Li Y; Xu P; Fang Q; Cao F; Lin H; Li Y; Su Y; Lu L; Chen L; Li Y; Zhao Z; Hong X; Li G; Tian Y; Sun J; Yan H; Fan Y; Zhang X; Li Z; Liu X
Nat Commun; 2024 Mar; 15(1):2177. PubMed ID: 38467604
[TBL] [Abstract][Full Text] [Related]
10. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Wise-Draper TM; Gulati S; Palackdharry S; Hinrichs BH; Worden FP; Old MO; Dunlap NE; Kaczmar JM; Patil Y; Riaz MK; Tang A; Mark J; Zender C; Gillenwater AM; Bell D; Kurtzweil N; Mathews M; Allen CL; Mierzwa ML; Casper K; Jandarov R; Medvedovic M; Lee JJ; Harun N; Takiar V; Gillison M
Clin Cancer Res; 2022 Apr; 28(7):1345-1352. PubMed ID: 35338369
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial.
Ferrarotto R; Nagarajan P; Maronge JM; Johnson JM; Rosenthal DI; Myers JN; Gross ND
JAMA Otolaryngol Head Neck Surg; 2023 Sep; 149(9):847-849. PubMed ID: 37535378
[TBL] [Abstract][Full Text] [Related]
12. Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region.
Izumi T; Teramoto Y; Kamimura A; Doi R; Takai S; Mori T; Koizumi S; Kawahara Y; Aitake U; Lei X; Inomata N; Inafuku K; Nakamura Y
J Dermatol; 2024 Feb; 51(2):271-279. PubMed ID: 38009848
[TBL] [Abstract][Full Text] [Related]
13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study.
Wu WJ; Liu Q; An PG; Wang L; Zhang JY; Chen Y; Zhang T; Zhang J
Front Immunol; 2023; 14():1282629. PubMed ID: 38035079
[TBL] [Abstract][Full Text] [Related]
16. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
Front Immunol; 2022; 13():970823. PubMed ID: 36389668
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
Kim CG; Hong MH; Kim D; Lee BH; Kim H; Ock CY; Kelly G; Bang YJ; Kim G; Lee JE; Kim C; Kim SH; Hong HJ; Park YM; Sim NS; Park H; Park JW; Lee CG; Kim KH; Park G; Jung I; Han D; Kim JH; Cha J; Lee I; Kang M; Song H; Oum C; Kim S; Kim S; Lim Y; Kim-Schulze S; Merad M; Yoon SO; Kim HJ; Koh YW; Kim HR
Clin Cancer Res; 2024 May; 30(10):2097-2110. PubMed ID: 38457288
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
Ju WT; Xia RH; Zhu DW; Dou SJ; Zhu GP; Dong MJ; Wang LZ; Sun Q; Zhao TC; Zhou ZH; Liang SY; Huang YY; Tang Y; Wu SC; Xia J; Chen SQ; Bai YZ; Li J; Zhu Q; Zhong LP
Nat Commun; 2022 Sep; 13(1):5378. PubMed ID: 36104359
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
